Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism

Inclusion Criteria: * Chronic kidney disease (CKD) patients with iPTH \>=300 pg/mL, adjusted calcium \>=8.4 to \<10.2 mg/dL, and phosphorus \<=6.5 mg/dL * Patients receiving dialysis 3 times weekly for at least 3 months before informed consent was obtained and scheduled to receive the same hemodialysis during the study period * Patients using dialysate with constant concentration of calcium for 4 weeks before informed consent was obtained and receiving phosphate binder with constant dose regimen for 2 weeks before informed consent was obtained Exclusion Criteria: * Patients taking drugs that affect iPTH, calcium, or bone metabolism * Patients with a history of allergic reaction or significant sensitivity to vitamin D * Patients who received parathyroidectomy or ethanol infusion within 1 year before informed consent was obtained * Patients with malignancy or with clinically significant hepatic disease (liver function tests more than 3 times the upper limit of normal) or with refractory hepatic disease * Patients with cardiovascular disease designated as New York Heart Association Class III or IV or with any of the following cardiovascular or cerebrovascular diseases within 6 months before informed consent was obtained: * Acute coronary syndrome (myocardial infarction or unstable angina) or acute cerebral vascular disease (cerebral infarction or cerebral hemorrhage) * Coronary arterial revascularization (such as coronary artery bypass grafting, percutaneous transluminal coronary angioplasty) * Cerebral arterial revascularization (such as cerebral aneurysm clipping, cerebral aneurysm embolization, carotid artery endarterectomy) * Arteriosclerosis obliterans with rest pain (Fontaine classification III or more severe) * Patients with severe hypertension (defined as mean resting blood pressure taken with the patient in a supine position before dialysis and at 6 dialyses sessions before informed consent was obtained: systolic \>= 180 mmHg and diastolic \>= 110 mmHg) * Patients with uncontrolled diabetes mellitus (defined as mean glycosylated hemoglobin \>=8% for 3 months before informed consent was obtained) * Patients with a history of drug or alcohol abuse within 6 months before informed consent was obtained * Patients who require chronic use of cytochrome P450 (CYP3A) inhibitors or inducers * Patients who are taking products that contain aluminum 2 weeks before informed consent was obtained * Patients who have taken paricalcitol in the past